Multiple system atrophy (MSA) is a sporadic multi-system progressive and uniformly fatal disorder characterized by autonomic failure, with orthostatic hypotension, neurogenic bladder/erectile dysfunction, cerebellar ataxia, corticospinal dysfunction, plus parkinsonism or cerebellar degeneration. Neuropathologically, MSA is characterized by glial cytoplasmic inclusions (GCI) of abnormally aggregated o synuclein (a-syn). Current treatments approaches aimed at symptomatic relief do not stay progression of disease and death, so that strategy has shifted to approaches aimed at halting or reversing pathogenesis of MSA. Many lines of evidence highlight the pathological importance of a-syn aggregation. There is evidence to support roles for mitochondria! dysfunction and oxidative stress. A transgenic (tg) mouse model expressing human a-syn under the myelin basic protein (MBP) promoter is now available. These MBP-a-syn tg mice have been shown to exhibit the oligodendroglial aggregates of a-syn and motor deficits characteristic of MSA. A number of agents have shown promise in combating a-syn aggregation. Of particular interest is rifampicin, because of its ability to inhibit the formation of a-synuclein fibrils and disaggregate fibrils already formed. This has led to the hypothesis that the antibiotic will delay progression or reverse neurologic and autonomic functions and symptoms in MSA. This approach has been supported by recent studies demonstrating a reversal of pathology and function. We propose a double blind placebo controlled clinical trial of Rifampicin 600 mg per day for 12 months in 60 tolOO patients with MSA. The study cohort will comprise patients with relatively early MSA, defined by duration of disease (<4 years) and severity, to optimize chances of improvement. The primary endpoint will be part 1 of the Unified MSA Rating Scale (UMSARS1). Secondary endpoints will comprise changes in autonomic symptom scores (COMPASS_change_select), and other autonomic indices. This consortium brings together a unique collaboration of autonomic experts with expertise to undertake a key study on the pathogenesis of MSA. Such a study may only be possible because this consortium enables a collaborative synergistic relationship with the 4 institutions (Vanderbilt, Mayo, Harvard, New York) and its collaboration with the MSA PPG.

Public Health Relevance

This treatment trial will uniquely evaluate if the drug Rifampicin will stop or reverse neurologic progression of a rare and uniformly fatal disease, multiple system atrophy. The Consortium uniquely enables this study by bringing together a group of the nation's top experts, who together can recruit a sufficient number of MSA patients at a sufficiently early stage of the disease.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-HOP-Y)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
United States
Zip Code
Arnold, Amy C; Okamoto, Luis E; Gamboa, Alfredo et al. (2016) Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure. Hypertension 67:424-9
Palma, Jose-Alberto (2016) Not all dysautonomias are created equal. Clin Auton Res 26:83
Loavenbruck, Adam J; Singer, Wolfgang; Mauermann, Michelle L et al. (2016) Transthyretin amyloid neuropathy has earlier neural involvement but better prognosis than primary amyloid counterpart: an answer to the paradox? Ann Neurol 80:401-11
Okamoto, Luis E; Diedrich, André; Baudenbacher, Franz J et al. (2016) Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension: A Randomized Comparison With Midodrine. Hypertension 68:418-26
Gutiérrez, Joel V; Norcliffe-Kaufmann, Lucy; Kaufmann, Horacio (2016) Brainstem reflexes in familial dysautonomia. Reply to ""Evidence of brainstem dysfunction in patients with familial dysautonomia and carriers of the IKBKAP mutation"". Clin Neurophysiol 127:1749-50
Labbé, Catherine; Heckman, Michael G; Lorenzo-Betancor, Oswaldo et al. (2016) MAPT haplotype diversity in multiple system atrophy. Parkinsonism Relat Disord 30:40-5
Norcliffe-Kaufmann, Lucy; Palma, Jose-Alberto; Kaufmann, Horacio (2016) Mother-induced hypertension in familial dysautonomia. Clin Auton Res 26:79-81
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Palma, Jose-Alberto; Norcliffe-Kaufmann, Lucy; Kaufmann, Horacio (2016) An orthostatic hypotension mimic: The inebriation-like syndrome in Parkinson disease. Mov Disord 31:598-600
Norcliffe-Kaufmann, Lucy; Kaufmann, Horacio; Martinez, Jose et al. (2016) Autonomic Findings in Takotsubo Cardiomyopathy. Am J Cardiol 117:206-13

Showing the most recent 10 out of 114 publications